Stopping empiric antibiotics early nearly tripled antibiotic-free days in neutropenic fever, and 5-day oseltamivir prophylaxis matched 10 days in hospital exposures.
|Videos|December 26, 2017
What Makes Ridinilazole Unique?
Author(s)Contagion® Editorial Staff
Dr. Richard Vickers, explains what makes ridinilazole unique.
Advertisement
Dr. Richard Vickers, chief scientific officer of R&D at Summit Therapeutics, explains what makes ridinilazole unique.
Interview Transcript (modified slightly for readability):
“At Summit Therapeutics, we’re developing ridinilazole for the treatment of Clostridium difficile infection (CDI). Ridinilazole is a novel, highly-targeted spectrum of activity antibiotic for C. difficile infection, and what really makes ridinilazole so unique is that it has activity against C. difficile, but almost no other bacteria.
If we think back to what we were discussing earlier, we see collateral damage with broad-spectrum antibiotics—either those that precipitate the initial infections or the ones we’re using to treat CDI—but with ridinilazole we can target the offending pathogen; we kill C. difficile, but we don’t cause that collateral damage and that means that the niche that C. difficile can exploit starts to dissipate. We then minimize the risk of recurrent disease, and it gives us an opportunity to not only treat the initial infection but to reduce the recurrence of CDI. That’s what we’re really looking for here when thinking about developing new C. diff therapies: reservation of the microbiome, no further collateral damage, and allowing some level of natural recovery.”
Advertisement
Related to this article
In an ECOSPOR III analysis, all-cause hospitalization by week 4 fell to 3.4% with fecal microbiota spores vs 16.1% with placebo in recurrent C difficile infection.
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
In the phase 2 RePreve trial, Lumen Bioscience’s investigational oral biologic LMN-201 plus standard antibiotics achieved global cure in 83.3% of patients with C difficile infection vs 36.4% with placebo, and cut recurrence sixfold (9.1% vs 55.6%) with no drug-related serious adverse events.
Projected disease burden from declining childhood vaccine coverage shows increases in vaccine-preventable diseases. Benjamin Lopman, PhD, provides insights on how VaxImpactMap works and the potential long-term disease consequences of decreased immunization rates.
Advertisement
Advertisement
Trending on Contagion Live
1
Early Dual Therapy Shortens Staphylococcus aureus Bacteremia in SABEDTIO Trial
2
Ebola Update: DRC Outbreak Reaches 9735 Cases, Second Largest on Record
3
IDSA 2026 Guidance Makes Sulbactam-Durlobactam the Priority for CRAB Infections
4
ID Week Highlights Part 1
5